TREMFYA® (guselkumab) demonstrated sustained clinical and endoscopic remission through 3 years in moderately to severely active Crohn's disease
New long-term data showed clinical remission rates of up to 94% and endoscopic remission rates of up to 61% in adults with moderately to severely active Crohn's disease 88% of patients achieved 90-day corticosteroid-free clinical remission SPRING HOUSE, Pa., Oct. 12, 2026 /PRNewswire/ --...
Read original article on All News Releases →